Yana G. Najjar
机构: UPMC Hillman Cancer Center
每年引用次数
引用次数
引用: 2,564
H-指数: 17
I10-指数 : 21
出版物: 84
Isolated secondary CNS relapse in a case of stage I diffuse large B-cell lymphoma
Y. G. Najjar , K. Mittal , N. N. Faza , H. Dushkin
Case Reports 2014
2014
Accumulation of MDSC subsets in renal cell carcinoma correlates with grade and progression free survival, and is associated with intratumoral expression of IL-1β, IL-8 and CXCL5
Yana G Najjar , Patricia A Rayman , Charlie Tannenbaum , Xuefei Jia
Journal for ImmunoTherapy of Cancer 2 ( S3) 227
7
2014
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study.
Yana G Najjar , Kristina Navrazhina , Fei Ding , Roma Bhatia
Journal for ImmunoTherapy of Cancer 8 ( 1)
9
2020
Neoadjuvant treatment for melanoma: current challenges and future perspectives.
Yana G Najjar , John M Kirkwood
Melanoma management 3 ( 2) 149 -159
2
2016
Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review.
Peter Mohr , Felix Kiecker , Virtudes Soriano , Olivier Dereure
Melanoma management 6 ( 4)
3
2019
Radiomic analysis of patient and inter-organ heterogeneity in response to immunotherapies and BRAF targeted therapy in metastatic melanoma
Alexandra Tompkins , Zane N Gray , Rebekah E Dadey , Serafettin Zenkin
medRxiv 2024.04. 26.24306411 -2024.04. 26.24306411
2024
Abstract LB062: Efficacy of Responder-derived Fecal Microbiota Transplant (R-FMT) and Pembrolizumab in Anti-PD-1 Refractory Patients with Advanced Melanoma
Diwakar Davar , Amiran Dzutsev , John A McCulloch , Richard R Rodrigues
Cancer Research 81 ( 13_Supplement) LB062 -LB062
2
2021
Efficacy of Responder-derived Fecal Microbiota Transplant (R-FMT) and Pembrolizumab in Anti-PD-1 Refractory Patients with Advanced Melanoma.
Diwakar Davar , Amiran Dzutsev , John A McCulloch , Richard R Rodrigues
CANCER RESEARCH 81 ( 13)
2021
A randomized phase 2 trial of encorafenib+ binimetinib+ nivolumab vs ipilimumab+ nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.
Zeynep Eroglu , James Moon , Yana G Najjar , Rupesh Kotecha
Journal of Clinical Oncology 41 ( 16_suppl) TPS9603 -TPS9603
1
2023
Abstract CT109: First-in-class first-in-human phase 1 trial and translational study of the mono (ADP-ribose) polymerase-7 (PARP7) inhibitor RBN-2397 in patients with selected advanced solid tumors
Timothy A Yap , Andres Cervantes , Gerald S Falchook , Manish R Patel
Cancer Research 83 ( 8_Supplement) CT109 -CT109
2023
Obesity is associated with altered tumor metabolism in metastatic melanoma
Andrew W Hahn , Ashley V Menk , Dayana B Rivadeneira , Ryan C Augustin
Clinical Cancer Research 29 ( 1) 154 -164
14
2023
Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
Saba S Shaikh , Yan Zang , Janel Hanmer , Hong Wang
Frontiers in Oncology 12 1022496 -1022496
3
2022
A phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with advanced melanoma.
Saba Shaikh , Yan Zang , Janel Hanmer , Hong Wang
Journal of Clinical Oncology 39 ( 15_suppl) e21506 -e21506
2021
Adjuvant Systemic Therapy for High-Risk Melanoma Patients
Yana G Najjar , Ryan Massa , Vernon K Sondak , Alexander MM Eggermont
Cutaneous Melanoma 747 -766
2020
Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities
Zeynep Eroglu , Sheri L Holmen , Qing Chen , Nikhil I Khushalani
Pigment cell & melanoma research 32 ( 3) 458 -469
39
2019
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study
Xue Bai , Ahmed Shaheen , Charlotte Grieco , Paolo D d’Arienzo
EClinicalMedicine 65
1
2023
Advanced stage melanoma during pregnancy: Real-world management.
Jessica SW Borgers , Douglas Buckner Johnson , Elisabeth Livingstone , Elizabeth Iannotti Buchbinder
Journal of Clinical Oncology 42 ( 16_suppl) 9540 -9540
2024
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study
Xue Bai , Ahmed Shaheen , Charlotte Grieco , Paolo D d’Arienzo
Eclinicalmedicine 71
2024
LUMINOS-102: Lerapolturev with and without α-PD-1 in unresectable α-PD-1 refractory melanoma
Justin Moser , Ding Wang , CL Cowey , Evan Pisick
36 ( 1) 158 -158
2023
Automated Quantitative CD8+ Tumor-Infiltrating Lymphocytes and Tumor Mutation Burden as Independent Biomarkers in Melanoma Patients Receiving Front-Line Anti-PD-1 Immunotherapy
Dylan Fortman , Arivarasan Karunamurthy , Douglas Hartman , Hong Wang
The Oncologist oyae054 -oyae054
2024